ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB - PETACC 8

Fédération Francophone de Cancérologie Digestive (FFCD)0 个研究点目标入组 2,550 人开始时间: 2006年2月22日最近更新: 2017年1月16日

试验速览

暂无简介。

•- Patients with a KRAS wild-type tumor only (for patients to be enrolled after approval of amendment No. 3)
•- Inpatient or outpatient = 18 and < 71 years of age
•- Pathologically confirmed stage III colon adenocarcinoma, regardless of the EGFR status
•- Curative R0 resection performed at least 28 days prior to start of study drug treatment and between 14 and 56 days prior to randomization.
•- No prior chemotherapy
•- No prior abdominal or pelvic irradiation
•- WHO performance status: 0 or 1
•- Life expectancy of = 5 years
•- Patients with childbearing potential should use effective contraception during the study and the following 6 months
•- White blood cell count = 3 x 109/L with neutrophils = 1.5 x 109/L, platelet count = 100 x 109/L, hemoglobin = 9 g/dL (5,6 mmol/l)
•- Total bilirubin =1.5 x ULN (upper limit of normal)
•- ASAT and ALAT = 2.5 x ULN
•- Alkaline phosphatase = 1.5 x ULN
•- Serum creatinine = 1.5 x ULN
•- Carcinoembryogenic antigen (CEA) = 1.5 x ULN after surgery (during screening period)
•- Signed written informed consent obtained prior to any study specific screening procedures
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
•Metastatic spread at baseline assessment
•Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery or having received radiation therapy prior to surgery
•Presence of inflammatory bowel disease
•Known hypersensitivity reaction to any of the components of study treatments
•Pregnancy (absence to be confirmed by ß-hCG test) or breast-feeding period
•Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
•Previous malignancy in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
•Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
•History or current evidence on physical examination of central nervous system disease or peripheral neuropathy = grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0
•Any significant disease which, in the investigator’s opinion, would exclude the patient from the study

发起方

Fédération Francophone de Cancérologie Digestive (FFCD)